Table 4.

Number of events (death) at different follow-up times in patients treated with ruxolitinib or placebo/BAT in COMFORT I and COMFORT II trials

	Ruxolitinib		Placebo/BAT		HR (95% CI)	P
	Number of events	Total treated	Number of events	Total treated
At data cutoff
COMFORT I	10 (6.5%)	155	14 (9.1%)	154	0.67 (0.30–1.50)	NS
COMFORT II	6 (4%)	146	4 (5%)	73	0.70 (0.20–2.39)	NS
Median follow-up: 55 weeks (COMFORT I); 61.1 weeks (COMFORT II)
COMFORT I	13 (8.4%)	155	24 (15.6%)	154	0.50 (0.25–0.98)	0.04
COMFORT II	11 (8%)	146	4 (5%)	73	1.01 (0.32–3.24)	NS
Median follow-up: 2 years (COMFORT I); 3 years (COMFORT II)
COMFORT I	27 (17.4%)	155	41 (26.6%)	154	0.58 (0.36–0.95)	0.03
COMFORT II	29 (19.9%)	146	22 (30.1%)	73	0.48 (0.28–0.85)	0.009

Abbreviations: BAT, best available therapy; HR, hazard ratio; NS, not significant.